Skip to main content
Erschienen in: Journal of Neuro-Oncology 1/2016

04.03.2016 | Clinical Study

Which elderly newly diagnosed glioblastoma patients can benefit from radiotherapy and temozolomide? A PERNO prospective study

verfasst von: Enrico Franceschi, Roberta Depenni, Alexandro Paccapelo, Mario Ermani, Marina Faedi, Carmelo Sturiale, Maria Michiara, Franco Servadei, Giacomo Pavesi, Benedetta Urbini, Anna Pisanello, Girolamo Crisi, Michele A. Cavallo, Claudio Dazzi, Claudia Biasini, Federica Bertolini, Claudia Mucciarini, Giuseppe Pasini, Agostino Baruzzi, Alba A. Brandes, The PERNO Study Group

Erschienen in: Journal of Neuro-Oncology | Ausgabe 1/2016

Einloggen, um Zugang zu erhalten

Abstract

The role of temozolomide concurrent with and adjuvant to radiotherapy (RT/TMZ) in elderly patients with glioblastoma (GBM) remains unclear. We evaluated the outcome of patients >70 years in the context of the Project of Emilia-Romagna Region in Neuro-Oncology (PERNO), the first Italian prospective observational population-based study in neuro-oncology. For this analysis the criteria for selecting patients enrolled in the PERNO study were: age >70 years; PS 0–3; histologically confirmed GBM; postoperative radiotherapy (RT) after surgery with or without concomitant temozolomide (TMZ) or postsurgical TMZ alone. Between January 2009 and December 2010, 76 GBM elderly patients were identified in the prospective PERNO study. Twenty-three patients did not receive any treatment after surgery, and 53 patients received postsurgical treatments (25 patients received RT alone and 28 patients RT/TMZ). Median survival was 11.1 months (95 % CI 8.8–13.5), adding temozolomide concomitant and adjuvant to radiotherapy it was 11.6 months (95 % CI 8.6–14.6), and 9.3 months (95 % CI 8.1–10.6) in patients treated with RT alone (P = 0.164). However, patients with MGMT methylated treated with RT/TMZ obtained a better survival (17.2 months, 95 % CI 11.5–22.9) (P = 0.042). No difference in terms of survival were observed if patients with MGMT unmethylated tumor received RT alone, or RT/TMZ or, in MGMT methylated tumor, if patients received radiotherapy alone. In elderly patients RT/TMZ represent a widely used approach but it is effective with methylated MGMT tumors only.
Literatur
1.
Zurück zum Zitat Brandes AA, Franceschi E (2011) Primary brain tumors in the elderly population. Curr Treat Options Neurol 13:427–435CrossRefPubMed Brandes AA, Franceschi E (2011) Primary brain tumors in the elderly population. Curr Treat Options Neurol 13:427–435CrossRefPubMed
2.
Zurück zum Zitat Brandes AA, Compostella A, Blatt V et al (2006) Glioblastoma in the elderly: current and future trends. Crit Rev Oncol Hematol 60:256–266CrossRefPubMed Brandes AA, Compostella A, Blatt V et al (2006) Glioblastoma in the elderly: current and future trends. Crit Rev Oncol Hematol 60:256–266CrossRefPubMed
3.
Zurück zum Zitat Stupp R, Mason WP, van den Bent MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–996CrossRefPubMed Stupp R, Mason WP, van den Bent MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–996CrossRefPubMed
4.
Zurück zum Zitat Stupp R, Taillibert S, Kanner AA et al (2015) Maintenance therapy with tumor-treating fields plus temozolomide vs temozolomide alone for glioblastoma: a randomized clinical trial. JAMA 314:2535–2543CrossRefPubMed Stupp R, Taillibert S, Kanner AA et al (2015) Maintenance therapy with tumor-treating fields plus temozolomide vs temozolomide alone for glioblastoma: a randomized clinical trial. JAMA 314:2535–2543CrossRefPubMed
5.
Zurück zum Zitat Jordan JT, Gerstner ER, Batchelor TT et al (2015) Glioblastoma care in the elderly. Cancer 122:189–197 CrossRefPubMed Jordan JT, Gerstner ER, Batchelor TT et al (2015) Glioblastoma care in the elderly. Cancer 122:189–197 CrossRefPubMed
6.
Zurück zum Zitat Brandes AA, Franceschi E, Tosoni A et al (2009) Temozolomide concomitant and adjuvant to radiotherapy in elderly patients with glioblastoma: correlation with MGMT promoter methylation status. Cancer 115:3512–3518CrossRefPubMed Brandes AA, Franceschi E, Tosoni A et al (2009) Temozolomide concomitant and adjuvant to radiotherapy in elderly patients with glioblastoma: correlation with MGMT promoter methylation status. Cancer 115:3512–3518CrossRefPubMed
7.
Zurück zum Zitat Malmstrom A, Gronberg BH, Marosi C et al (2012) Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. Lancet Oncol 13:916–926CrossRefPubMed Malmstrom A, Gronberg BH, Marosi C et al (2012) Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. Lancet Oncol 13:916–926CrossRefPubMed
8.
Zurück zum Zitat Wick W, Platten M, Meisner C et al (2012) Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. Lancet Oncol 13:707–715CrossRefPubMed Wick W, Platten M, Meisner C et al (2012) Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. Lancet Oncol 13:707–715CrossRefPubMed
9.
Zurück zum Zitat Brandes AA, Franceschi E, Ermani M et al (2015) Pattern of care and effectiveness of treatment for glioblastoma patients in the real world: results from a prospective population-based registry. Could survival differ in a high-volume center? Neurooncol Pract 1:166–171 Brandes AA, Franceschi E, Ermani M et al (2015) Pattern of care and effectiveness of treatment for glioblastoma patients in the real world: results from a prospective population-based registry. Could survival differ in a high-volume center? Neurooncol Pract 1:166–171
10.
Zurück zum Zitat Horton NJ, Fitzmaurice GM (2004) Regression analysis of multiple source and multiple informant data from complex survey samples. Stat Med 23:2911–2933CrossRefPubMed Horton NJ, Fitzmaurice GM (2004) Regression analysis of multiple source and multiple informant data from complex survey samples. Stat Med 23:2911–2933CrossRefPubMed
11.
Zurück zum Zitat Hegi ME, Diserens AC, Gorlia T et al (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352:997–1003CrossRefPubMed Hegi ME, Diserens AC, Gorlia T et al (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352:997–1003CrossRefPubMed
12.
Zurück zum Zitat Keime-Guibert F, Chinot O, Taillandier L et al (2007) Radiotherapy for glioblastoma in the elderly. N Engl J Med 356:1527–1535CrossRefPubMed Keime-Guibert F, Chinot O, Taillandier L et al (2007) Radiotherapy for glioblastoma in the elderly. N Engl J Med 356:1527–1535CrossRefPubMed
13.
Zurück zum Zitat Roa W, Brasher PM, Bauman G et al (2004) Abbreviated course of radiation therapy in older patients with glioblastoma multiforme: a prospective randomized clinical trial. J Clin Oncol 22:1583–1588CrossRefPubMed Roa W, Brasher PM, Bauman G et al (2004) Abbreviated course of radiation therapy in older patients with glioblastoma multiforme: a prospective randomized clinical trial. J Clin Oncol 22:1583–1588CrossRefPubMed
14.
Zurück zum Zitat Roa W, Kepka L, Kumar N et al (2015) International Atomic Energy Agency Randomized Phase III Study of Radiation Therapy in elderly and/or frail patients with newly diagnosed glioblastoma multiforme. J Clin Oncol 33:4145CrossRefPubMed Roa W, Kepka L, Kumar N et al (2015) International Atomic Energy Agency Randomized Phase III Study of Radiation Therapy in elderly and/or frail patients with newly diagnosed glioblastoma multiforme. J Clin Oncol 33:4145CrossRefPubMed
15.
Zurück zum Zitat Arvold ND, Tanguturi SK, Aizer AA et al (2015) Hypofractionated versus standard radiation therapy with or without temozolomide for older glioblastoma patients. Int J Radiat Oncol Biol Phys 92:384–389CrossRefPubMed Arvold ND, Tanguturi SK, Aizer AA et al (2015) Hypofractionated versus standard radiation therapy with or without temozolomide for older glioblastoma patients. Int J Radiat Oncol Biol Phys 92:384–389CrossRefPubMed
Metadaten
Titel
Which elderly newly diagnosed glioblastoma patients can benefit from radiotherapy and temozolomide? A PERNO prospective study
verfasst von
Enrico Franceschi
Roberta Depenni
Alexandro Paccapelo
Mario Ermani
Marina Faedi
Carmelo Sturiale
Maria Michiara
Franco Servadei
Giacomo Pavesi
Benedetta Urbini
Anna Pisanello
Girolamo Crisi
Michele A. Cavallo
Claudio Dazzi
Claudia Biasini
Federica Bertolini
Claudia Mucciarini
Giuseppe Pasini
Agostino Baruzzi
Alba A. Brandes
The PERNO Study Group
Publikationsdatum
04.03.2016
Verlag
Springer US
Erschienen in
Journal of Neuro-Oncology / Ausgabe 1/2016
Print ISSN: 0167-594X
Elektronische ISSN: 1573-7373
DOI
https://doi.org/10.1007/s11060-016-2093-1

Weitere Artikel der Ausgabe 1/2016

Journal of Neuro-Oncology 1/2016 Zur Ausgabe

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Neu im Fachgebiet Neurologie

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.